Centro De Ingenieria Genetica Y Biotecnologia

Haydee Geronimo Perez

Alicia Santos Savio

Osvaldo Reyes Acosta

Silvio Ernesto Perea Rodriguez

Gerardo Enrique Guillen Nieto

Jorge Amador Berlanga Acosta

Hilda Elisa Garay Perez

Luis Saturnino Herrera Martinez

Jose Ignacio Fernandez Montequin

Ania Cabrales Rico

Hector Santana Milian

Ingrid Rojas Constantin

Yunier Rodriguez Alvarez

Jorge Sotolongo Pena

Jose Rafael Martinez Castillo

Alejandro Moro Soria

Calixto Valdes Perez

Neobalis Franco Perez

Larissa Chacon Corvea

Gerardo Enríque Guillen Nieto

Leonardo Canan-Haden Frias

Celia Aurora Arrieta Aguero

Ricardo Silva Rodriguez

Yanelis Morera Diaz

Armando Alexei Rodriquez Alfonso

The present invention is related to the field of molecular immunology, particularly to a peptide derived from the sequence of interleukine-15 (IL-15), wherein said peptide was optimized to inhibit the biological activity of this molecule. In the present invention, it is shown that this peptide inhibits IL-15-induced T cell proliferation, Tumor Necrosis Factor &#x3b1; (TNF&#x3b1;) induction and the expression of IL-8 and IL-6 by the IL-15 receptor &#x3b1; subunit (IL-15R&#x3b1;), all these effects mediated by the binding of the peptide to the IL-15R&#x3b1;. The invention is also related to the use of the peptide to treat pathologies where the abnormal expression of IL-15 or IL-15R&#x3b1; is related to the course of the disease, such as rheumatoid arthritis (RA) and prostate cancer.

Peptide antagonist of interleukin-15 activity

Vaccine composition containing IL-15 for active immunization to treatment diseases related to over-expression of this cytokine. The technical aim pursued in this invention is to inhibit IL-15 activity through development of a therapeutic vaccine which elicits IL-15 neutralizing antibodies in the immunized host. IL-15 can be presented in this vaccine composition either alone or coupled to a carrier such as the P64k protein with a vaccine adjuvant such as Aluminum hydroxide. Besides, this invention is related to the use of this vaccine for treatment of Rheumatoid arthritis and other IL-15 over-expressing related diseases, and leukemia, where this cytokine acts as a growth factor.

Vaccine composition comprising interleukin-15 (IL-15)

The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect of acute reperfusion with oxygenated blood following prolonged ischaemia, thereby preventing further surgical procedures and favoring the preservation of the extremity. The aforementioned composition can be used to improve (i) the cell microenvironment, thereby increasing the reparative and defensive capacity and viability of the is tissues and (ii) the cicatrization of cutaneous ischaemic lesions, thereby stimulating cell proliferation. The invention is suitable for use in human, veterinary and experimental medicine, specifically in vascular angiology and surgery, dermatology, burn treatment and reconstructive surgery and geriatric medicine. Said composition can be used for recalcitrant ulcers which are associated with lesions in the macro and/or microvasculature, patients with inadequate lymphatic and/or venous return and ulcers or other lesions which are difficult to cicatrize and/or heal.

Use of pharmaceutical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention

Current invention is related to the molecular pharmacology branch particularly to a peptide belonging to the Interleukin-15 sequence (IL-15) which is able to inhibit IL-15 biological activity, analogues or mimetic of such peptides. In the current invention it is shown that the peptide inhibits both IL-15-induced T cells proliferation upon binding to the IL15 receptor a subunit (IL15R&#x3b1;) and TNF&#x3b1;-mediated apoptosis. Besides, this invention is related to the use of this peptide in the treatment of several pathologies where aberrant IL-15 or IL-15R&#x3b1; expression is associated to the disease progression.

Interleukin-15 antagonist peptide

Growing community of inventors

Ciudad de la Habana, Cuba

Haydee Geronimo Perez